Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapyGordon Cook, A. John Ashcroft, Guy Pratt et al.|British Journal of Haematology|2020Cited by 111
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, Rakesh Popat, Sumaiya Kamora et al.|The Lancet Haematology|2022Cited by 25
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A. Chapman, Kwee Yong, Jonathan Sive et al.|Blood|2018Cited by 20
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Kwee Yong, María Cuadrado et al.|British Journal of Haematology|2021Cited by 15
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon StudyKwee Yong, Roger G. Owen, Rakesh Popat et al.|Blood|2019Cited by 8